ArticleScientific reports2026
Facile synthesis of Sarcochlamys pulcherrima mediated silver nanoparticles for antibacterial, antibiofilm, and network pharmacology evaluation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Green synthesis of nanoparticles (NPs) has transpired as aneconomical, efficient and environmentally friendlycompared to conventional methods. In this study, Sarcochlamys pulcherrima leaf extract was made to be used as a natural reducing and capping agent to fabricate silver nanoparticles (sp-AgNPs), which were further evaluated for antibacterial and antibiofilm activities. The sp-AgNPs were synthesized via two ways; Heating at 80 °C and Non-heating methodsto evaluate the particle size difference on the antibacterial and antibiofilm efficacy.The sp-AgNPs were characterized using standard techniques ofUV-Vis spectroscopy, Energy Dispersive Spectroscopy (EDX), Dynamic Light Scattering (DLS), Zeta Potential, and Scanning Electron Microscopy (SEM). The colour change pre and post synthesis and subsequent characteristic UV-Vis peaks confirmed successful nanoparticle formation. Zeta and SEM analyses of sp-AgNPs revealed average sizes of 37.6-45.1 nm for Heat and 44.7-53.9 nm for Non-heatwith spherical, needle-like morphology. EDX confirmed the presence of silver ionin sp-AgNPs. Antibacterial assays against B.subtilis, S.aureus, P.aeruginosa, and E.coli showed inhibitory zones with both synthesis methods. The Minimum Inhibitory Concentration (MIC) and Maximum Bactericidal Concentration (MBC) for sp-AgNPs wereevaluated and antibiofilm activity performed.Superior biofilm inhibition of 67.51-83.14%was demonstrated by Non-heatingsynthesismethod compared to 50.93-73.76% reduction bythe heatmethod.Further, the Liquid Chromatography-Tandem Mass Spectroscopy (LC-MS/MS) data and Network pharmacology identified key antibacterial phytoconstituents targeting immune and metabolic pathways like AKT1, STAT3, and CASP3. Overall, this study demonstrates a facile green synthesis of sp-AgNPs with potent antibacterial and antibiofilm potential which can be harnessed for future biomedical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.